Level Four Advisory Services LLC Has $310,000 Stake in GSK plc (NYSE:GSK)

Level Four Advisory Services LLC boosted its stake in GSK plc (NYSE:GSK) by 5.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,152 shares of the pharmaceutical company’s stock after acquiring an additional 511 shares during the quarter. Level Four Advisory Services LLC’s holdings in GSK were worth $310,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. United Bank boosted its position in shares of GSK by 7.3% during the third quarter. United Bank now owns 25,785 shares of the pharmaceutical company’s stock worth $1,054,000 after buying an additional 1,760 shares during the period. Charles Schwab Investment Management Inc. boosted its position in GSK by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,603 shares of the pharmaceutical company’s stock worth $4,971,000 after acquiring an additional 14,687 shares during the last quarter. CreativeOne Wealth LLC bought a new position in shares of GSK during the 3rd quarter worth approximately $213,000. Fred Alger Management LLC raised its holdings in shares of GSK by 9.1% in the third quarter. Fred Alger Management LLC now owns 44,801 shares of the pharmaceutical company’s stock valued at $1,831,000 after purchasing an additional 3,733 shares during the last quarter. Finally, Atom Investors LP acquired a new stake in shares of GSK in the third quarter valued at approximately $296,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GSK shares. Morgan Stanley began coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Up 0.2 %

GSK stock opened at $38.81 on Tuesday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93. The firm has a market capitalization of $80.33 billion, a PE ratio of 24.41, a P/E/G ratio of 1.12 and a beta of 0.58. The company’s 50-day moving average is $37.33 and its 200-day moving average is $36.66. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Sell-side analysts anticipate that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.05%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s payout ratio is 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.